Mallinckrodt Plc - New
MNK
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.52M
Close$
Share Statistics
| Market cap | $4.52 Million |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.48 |
| Beta | 0 |
| Outstanding Shares | 39,600,000 |
Return
| Return on Equity | -29.38% |
|---|---|
| Return on Assets | -10.51% |
| Return on Invested Capital | -11.44% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.18 |
| Enterprise Value to EBIT | -3.14 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 1.47 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Mallinckrodt Plc
3,600 employees
CEO: Mark Trudeau Mallinckrodt Pharmaceuticals is an Irish–tax registered manufacturer of specialty pharmaceuticals , generic drugs and imaging agents. In 2017 it generated 90% of sales from the U.S. healthcare system. While Mallinckrodt is headquartered ...